Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05013450 · ClinicalTrials.gov registry record · Phase 1

Dupilumab_Metastatic NSCLC

A Phase 1 study of Metastatic Non Small Cell Lung Cancer, sponsored by Thomas Marron.

Active
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT05013450 is a Phase 1 study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Thomas Marron. The registered enrollment target is 33 participants, below the 393-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05013450, a Phase 1 study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Thomas Marron.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

This is a multi cohort, sequential enrollment clinical trial to determine the safety and tolerability of Dupilumab and Anakinra with PD-(L)1 blockade for patients with relapsed/refractory metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra and IL-1R blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents.

Conditions Studied

Metastatic Non Small Cell Lung Cancer

Interventions

  • DRUG Dupilumab
  • DRUG Anakinra
  • DRUG PD-1/PD-L1 blockade

Study Locations (1)

New York

  • Tisch Cancer Institute, Mount Sinai Hospital - New York

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2021-09-10
Est. Completion 2025-12-09
Phase Phase 1

Sponsor

Thomas Marron

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05013450

The ClinicalTrials.gov registry entry for NCT05013450 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Thomas Marron, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dupilumab is the first listed.

NCT05013450 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05013450 about?

NCT05013450 is a clinical study titled "Dupilumab_Metastatic NSCLC". This is a multi cohort, sequential enrollment clinical trial to determine the safety and tolerability of Dupilumab and Anakinra with PD-(L)1 blockade for patients with relapsed/refractory metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra and IL-1R blockade to PD-(L)1 blocking a...

What is the current status of trial NCT05013450?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2021-09-10. Estimated completion is 2025-12-09.

What conditions does trial NCT05013450 study?

This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT05013450?

The interventions under investigation include: Dupilumab (DRUG), Anakinra (DRUG), PD-1/PD-L1 blockade (DRUG).

Who is sponsoring clinical trial NCT05013450?

This trial is sponsored by Thomas Marron, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05013450 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Non Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Non Small Cell Lung Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.